TY - JOUR
T1 - Incidence of a first venous thrombotic event in people with HIV in the Netherlands
T2 - a retrospective cohort study
AU - ATHENA observational HIV cohort investigators
AU - Howard, Jaime F.Borjas
AU - Rokx, Casper
AU - Smit, Colette
AU - Wit, Ferdinand W.N.M.
AU - Pieterman, Elise D.
AU - Meijer, Karina
AU - Rijnders, Bart
AU - Bierman, Wouter F.W.
AU - Tichelaar, Y. I.G.Vladimir
AU - Van der Valk, M.
AU - Van Kasteren, M. E.E.
AU - Schippers, E. F.
AU - Leyten, E. M.S.
AU - Kroon, F. P.
AU - Den Hollander, J. G.
AU - Lowe, S. H.
AU - Mulder, J. W.
AU - Brinkman, K.
AU - Gisolf, E. H.
AU - Reiss, P.
AU - Zaheri, S.
AU - Hillebregt, M.
AU - van der Ende, M. E.
PY - 2019/3
Y1 - 2019/3
N2 - Background: The risk of venous thrombotic events is elevated in people with HIV, but overall risk estimates and estimates specific to immune status and antiretroviral medication remain i mprecise. In this study, we aimed to estimate these parameters in a large cohort of people with HIV in the Netherlands. Methods: In this retrospective cohort study, we used the Dutch ATHENA cohort to estimate crude, age and sex standardised, and risk period-specific incidences of a first venous thrombotic event in people with HIV aged 18 years or older attending 12 HIV treatment centres in the Netherlands. Crude and standardised incidences were compared with European population-level studies of venous thrombotic events. We used time-updated Cox regression to estimate the risk of a first venous thrombotic event in association with HIV-specific factors (CD4 cell count, viral load, recent opportunistic infections, antiretroviral medication use) adjusted for traditional risk factors for venous thrombotic events. Findings: With data collected from Jan 1, 2003, to April 1, 2015, our study cohort included 14 389 people with HIV and 99 762 person-years of follow-up, with a median follow-up of 7·2 years (IQR 3·3–11·1). During this period, 232 first venous thrombotic events occurred, yielding a crude incidence of 2·33 events per 1000 person-years (95% CI 2·04–2·64) and an incidence standardised for age and sex of 2·50 events per 1000 (2·18–2·82). CD4 counts less than 200 cells per μL were independently associated with higher risk of a venous thrombotic event: adjusted hazard ratio (aHR) 3·40 (95% CI 2·28–5·08) relative to counts of 500 cells per μL. A high viral load (aHR 3·15, 95% CI 2·00–5·02; >100 000 copies per mL vs <50 copies per mL) and current or recent opportunistic adverse events (2·80, 1·77–4·44) were also independently associated with higher risk of a venous thrombotic event. There were no associations between any specific antiretroviral drugs and risk of a venous thrombotic event. Rates associated with pregnancy (9·4, 95% CI 4·6–17·3), malignancy (16·7, 10·6–25·1), and hospitalisation (24·4, 19·1–30·6) were lower than primary thromboprophylaxis thresholds suggested by the respective guidelines. Interpretation: Our findings support neither prescribing primary outpatient thromboprophylaxis nor avoiding any type of antiretroviral medication in people with HIV at high risk of a venous thrombotic event. Funding: Dutch Ministry of Health, Welfare and Sport.
AB - Background: The risk of venous thrombotic events is elevated in people with HIV, but overall risk estimates and estimates specific to immune status and antiretroviral medication remain i mprecise. In this study, we aimed to estimate these parameters in a large cohort of people with HIV in the Netherlands. Methods: In this retrospective cohort study, we used the Dutch ATHENA cohort to estimate crude, age and sex standardised, and risk period-specific incidences of a first venous thrombotic event in people with HIV aged 18 years or older attending 12 HIV treatment centres in the Netherlands. Crude and standardised incidences were compared with European population-level studies of venous thrombotic events. We used time-updated Cox regression to estimate the risk of a first venous thrombotic event in association with HIV-specific factors (CD4 cell count, viral load, recent opportunistic infections, antiretroviral medication use) adjusted for traditional risk factors for venous thrombotic events. Findings: With data collected from Jan 1, 2003, to April 1, 2015, our study cohort included 14 389 people with HIV and 99 762 person-years of follow-up, with a median follow-up of 7·2 years (IQR 3·3–11·1). During this period, 232 first venous thrombotic events occurred, yielding a crude incidence of 2·33 events per 1000 person-years (95% CI 2·04–2·64) and an incidence standardised for age and sex of 2·50 events per 1000 (2·18–2·82). CD4 counts less than 200 cells per μL were independently associated with higher risk of a venous thrombotic event: adjusted hazard ratio (aHR) 3·40 (95% CI 2·28–5·08) relative to counts of 500 cells per μL. A high viral load (aHR 3·15, 95% CI 2·00–5·02; >100 000 copies per mL vs <50 copies per mL) and current or recent opportunistic adverse events (2·80, 1·77–4·44) were also independently associated with higher risk of a venous thrombotic event. There were no associations between any specific antiretroviral drugs and risk of a venous thrombotic event. Rates associated with pregnancy (9·4, 95% CI 4·6–17·3), malignancy (16·7, 10·6–25·1), and hospitalisation (24·4, 19·1–30·6) were lower than primary thromboprophylaxis thresholds suggested by the respective guidelines. Interpretation: Our findings support neither prescribing primary outpatient thromboprophylaxis nor avoiding any type of antiretroviral medication in people with HIV at high risk of a venous thrombotic event. Funding: Dutch Ministry of Health, Welfare and Sport.
UR - http://www.scopus.com/inward/record.url?scp=85061554727&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/S2352-3018(18)30333-3
DO - https://doi.org/10.1016/S2352-3018(18)30333-3
M3 - Article
C2 - 30777727
SN - 2352-3018
VL - 6
SP - e173-e181
JO - The Lancet HIV
JF - The Lancet HIV
IS - 3
ER -